OFM
Omega Fund Management Portfolio holdings
AUM
$154M
This Quarter Return
-9.44%
1 Year Return
-32.78%
3 Year Return
+82.35%
5 Year Return
+29.08%
10 Year Return
+90.46%
AUM
$135M
AUM Growth
+$135M
(-6.5%)
Cap. Flow
+$6.44M
Cap. Flow
% of AUM
4.77%
Top 10 Holdings %
Top 10 Hldgs %
99.5%
Holding
11
New
–
Increased
3
Reduced
1
Closed
–
Top Buys
| 1 |
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
|
$6.42M |
| 2 |
EGLT
Egalet Corporation
EGLT
|
$372K |
| 3 |
Editas Medicine
EDIT
|
$24 |
Top Sells
| 1 |
PVLA
Palvella Therapeutics, Inc. Common Stock
PVLA
|
$356K |
Sector Composition
| 1 | Healthcare | 64.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
JUNO
1
DELISTED
Juno Therapeutics, Inc.
JUNO
| $47.3M | 35.06% | 1,229,512 | – | – |
|
|
PRTK
2
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $36.2M | 26.83% | 2,600,410 +461,538 | +22% | +$6.42M |
|
|
EGLT
3
DELISTED
Egalet Corporation
EGLT
| $14.3M | 10.63% | 2,889,926 +74,998 | +3% | +$372K |
|
4
FibroGen
FGEN
$47.8M
| $13.5M | 10.01% | 822,175 | – | – |
|
|
NBRV
5
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $8.59M | 6.38% | 1,145,890 | – | – |
|
6
ESSA Pharma
EPIX
$11.4M
| $5.01M | 3.71% | 1,696,969 | – | – |
|
|
PVLA
7
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $3.64M | 2.7% | 2,262,832 -221,117 | -9% | -$356K |
|
|
8
Editas Medicine
EDIT
$231M
| $2.56M | 1.9% | 105,008 +1 | +0% | +$24 |
|
9
Protara Therapeutics
TARA
$120M
| $2.01M | 1.49% | 250,000 | – | – |
|
|
CBAY
10
DELISTED
Cymabay Therapeutics
CBAY
| $1.06M | 0.78% | 606,100 | – | – |
|
|
DRNA
11
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $670K | 0.5% | 223,457 | – | – |
|